vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research note published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $6.00 target price on shares of vTv Therapeutics in a research note on Tuesday, March 7th.

vTv Therapeutics Trading Down 2.7 %

VTVT opened at $0.78 on Thursday. The stock has a 50-day moving average price of $0.87 and a 200-day moving average price of $0.87. vTv Therapeutics has a 12-month low of $0.38 and a 12-month high of $1.40.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last released its earnings results on Monday, March 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $0.01 million during the quarter. On average, research analysts anticipate that vTv Therapeutics will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp raised its position in vTv Therapeutics by 268.7% during the 2nd quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 150,228 shares during the last quarter. Millennium Management LLC raised its position in vTv Therapeutics by 12.0% during the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 14,845 shares during the last quarter. Prudential Financial Inc. bought a new position in vTv Therapeutics during the 2nd quarter valued at approximately $30,000. Finally, HBK Sorce Advisory LLC bought a new position in vTv Therapeutics during the 4th quarter valued at approximately $38,000. Institutional investors own 8.50% of the company’s stock.

About vTv Therapeutics

(Get Rating)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.